corticotropin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4931	9002-60-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: corticotropin ACTH corticotrophin adrenocorticotrophic hormone acthar gel cortrophin corticotropin zinc hydroxide corticotropin-zinc hydroxide cortrophin-zinc	A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress. Molecular weight: 4541.14 Formula: C207H308N56O58S CLOGP: LIPINSKI: None HAC: 114 HDO: 63 TPSA: 1836.25 ALOGS: ROTB: 145

Molecule

Description

Molfile Inchi Smiles

Synonyms:

corticotropin
ACTH
corticotrophin
adrenocorticotrophic hormone
acthar gel
cortrophin
corticotropin zinc hydroxide
corticotropin-zinc hydroxide
cortrophin-zinc

A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress.

Molecular weight: 4541.14
Formula: C207H308N56O58S
CLOGP:
LIPINSKI: None
HAC: 114
HDO: 63
TPSA: 1836.25
ALOGS:
ROTB: 145

Drug dosage:

Dose	Unit	Route
25	U	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 3, 1950	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	94.23	20.25	58	5007	42067	46638930
Injection site bruising	76.97	20.25	48	5017	35588	46645409
Infantile spasms	66.63	20.25	13	5052	250	46680747
Therapy cessation	57.81	20.25	36	5029	26593	46654404
Weight increased	46.58	20.25	72	4993	164401	46516596
Epidural lipomatosis	43.87	20.25	8	5057	105	46680892
Swelling face	41.48	20.25	39	5026	53020	46627977
Product dose omission issue	41.18	20.25	69	4996	168451	46512546
Blood glucose increased	39.99	20.25	44	5021	71969	46609028
Sarcoidosis	38.23	20.25	16	5049	5143	46675854
Fluid retention	33.32	20.25	34	5031	51012	46629985
Peripheral swelling	31.22	20.25	59	5006	158012	46522985
Visual impairment	29.08	20.25	36	5029	66653	46614344
Cushingoid	29.05	20.25	14	5051	6252	46674745
Swelling	23.98	20.25	46	5019	124465	46556532
Insomnia	23.67	20.25	54	5011	164870	46516127
Opsoclonus myoclonus	23.62	20.25	5	5060	146	46680851
Nail pigmentation	22.33	20.25	5	5060	191	46680806
Atonic seizures	21.02	20.25	6	5059	614	46680383

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infantile spasms	79.53	25.62	14	1755	285	29950424
Fluid retention	47.37	25.62	25	1744	24973	29925736
Blood glucose increased	39.30	25.62	31	1738	61499	29889210
Weight increased	37.97	25.62	33	1736	74880	29875829
Irritability	35.21	25.62	20	1749	23030	29927679
Drug ineffective	34.39	25.62	67	1702	340320	29610389
Insomnia	33.60	25.62	34	1735	93302	29857407
Intramyelinic oedema	32.18	25.62	4	1765	4	29950705
Hypertension	29.51	25.62	36	1733	121318	29829391
Injection site bruising	28.32	25.62	12	1757	7326	29943383
Therapy cessation	28.25	25.62	15	1754	15122	29935587
Nephrotic syndrome	25.71	25.62	11	1758	6874	29943835

Pharmacologic Action:

Source	Code	Description
ATC	H01AA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ACTH
FDA CS	M0000499	Adrenocorticotropic Hormone
CHEBI has role	CHEBI:33295	diagnostic aid
FDA EPC	N0000175941	Adrenocorticotropic Hormone

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
West syndrome	indication	28055006
Stevens-Johnson syndrome	indication	73442001	DOID:0050426
Exacerbation of multiple sclerosis	indication	192929006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.15	acidic
pKa2	3.37	acidic
pKa3	3.62	acidic
pKa4	3.86	acidic
pKa5	4.07	acidic
pKa6	4.31	acidic
pKa7	4.6	acidic
pKa8	9.43	acidic
pKa9	10.05	acidic
pKa10	12.25	acidic
pKa11	12.36	acidic
pKa12	12.63	acidic
pKa13	12.69	acidic
pKa14	12.93	acidic
pKa15	13.11	acidic
pKa16	13.11	acidic
pKa17	13.22	acidic
pKa18	13.41	acidic
pKa19	13.55	acidic
pKa20	13.6	acidic
pKa21	13.66	acidic
pKa22	13.75	acidic
pKa23	13.76	acidic
pKa24	13.79	acidic
pKa25	13.89	acidic
pKa26	14.0	acidic
pKa27	11.5	Basic
pKa28	11.26	Basic
pKa29	11.01	Basic
pKa30	10.81	Basic
pKa31	10.55	Basic
pKa32	10.3	Basic
pKa33	9.94	Basic
pKa34	7.62	Basic
pKa35	6.69	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Adrenocorticotropic hormone receptor	GPCR	Q01718	ACTHR_HUMAN	AGONIST			UNKNOWN	IUPHAR
Melanocyte-stimulating hormone receptor	GPCR	Q01726	MSHR_HUMAN	AGONIST	Ki	8.60	IUPHAR
Melanocortin receptor 3	GPCR	P41968	MC3R_HUMAN	AGONIST	Ki	7.06	IUPHAR
Melanocortin receptor 4	GPCR	P32245	MC4R_HUMAN	AGONIST	Ki	6.16	IUPHAR

External reference:

ID	Source
D00146	KEGG_DRUG
4018523	VUID
N0000146845	NUI
12427-33-7	SECONDARY_CAS_RN
4018523	VANDF
4022410	VANDF
C0001655	UMLSCUI
CHEBI:3892	CHEBI
CHEMBL1201610	ChEMBL_ID
CHEMBL1201609	ChEMBL_ID
DB01285	DRUGBANK_ID
16132265	PUBCHEM_CID
3633	IUPHAR_LIGAND_ID
1366	INN_ID
471	INN_ID
K0U68Q2TXA	UNII
376	RXNORM
2492	MMSL
326050	MMSL
4506	MMSL
4507	MMSL
84	MMSL
d00604	MMSL
002113	NDDF
002114	NDDF
126187000	SNOMEDCT_US
40789008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
1 Detoxification	HUMAN OTC DRUG LABEL	81	55146-011	LIQUID	30 [hp_C]	ORAL	unapproved homeopathic	9 sections
Acthar	HUMAN PRESCRIPTION DRUG LABEL	1	63004-8710	INJECTION	80 [USPU]	INTRAMUSCULAR	NDA	26 sections